

Performance (consolidated)

(¥ million)

	2018 (JGAAP)	2019 (JGAAP)	2020 (IFRS)	2021 (IFRS)	2022 (IFRS)	2023 (IFRS)	2024 (IFRS) (estimated)
Revenue	114,716	116,637	121,859	137,484	144,175	148,255	150,000
Operating profit	20,644	21,668	27,702	32,948	30,049	33,295	31,000
Profit before tax	21,540	22,442	27,608	33,301	30,489	33,616	31,500
Profit attributable to owners of parent	16,302	16,866	19,540	24,986	22,812	25,851	24,500

May 10, 2024

(¥ million)

Brand name	Active Ingredient	Indications	Launch Date	Sales 2022 (IFRS)	Sales 2023 (IFRS)	Sales 2024 (IFRS) (estimated)	
						Apr-Sep	Annual
Viltepso	viltolarsen	Duchenne muscular dystrophy	Japan May-2020 U.S. Aug-2020	14,341	17,530	9,800	20,100
(Japan)				(4,139)	(4,407)	(2,300)	(4,600)
(U.S.)				(10,201)	(13,123)	(7,500)	(15,500)
Uptravi	selexipag	pulmonary arterial hypertension/ chronic thromboembolic pulmonary hypertension	Nov-2016/ Aug-2021	10,543	12,918	7,600	15,400
Vidaza	azacitidine	myelodysplastic syndrome/ acute myeloid leukemia	Mar-2011/ Mar-2021	15,951	10,383	2,600	4,800
Gazyva	obinutuzumab	CD20-positive follicular lymphoma/ CD20-positive chronic lymphocytic leukemia	Aug-2018/ Dec-2022	4,904	4,695	2,500	5,100
Tramal, Onetram	tramadol hydrochloride	cancer pain, chronic pain	Sep-2010	5,358	3,927	1,400	2,700
Cialis	tadalafil	erectile dysfunction	Jul-2009	2,938	2,499	1,400	2,700
Erizas	dexamethasone cipeclilate	allergic rhinitis	Dec-2009	2,640	2,284	700	2,100
Zalutia	tadalafil	urinary disorder caused by benign prostatic hyperplasia	Apr-2014	2,826	2,256	850	1,600
Adcirca	tadalafil	pulmonary arterial hypertension	Dec-2009	2,649	2,255	900	1,700
Defitelio	defibrotide sodium	sinusoidal obstruction syndrome	Sep-2019	2,524	2,221	1,100	2,300
Profit in co-promotion				9,520	8,658	4,550	9,100
Revenues from the licensing of industrial property rights				30,714	40,304	20,600	41,700
Pharmaceuticals				121,988	125,105	62,800	128,500
Functional Food				22,187	23,150	10,500	21,500
Revenue				144,175	148,255	73,300	150,000